Appointment of Dr. Ian Gilham as Chairman of the Board at Biosurfit

Biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today the appointment of Dr. Ian Gilham as Chairman of the Board.

Previously, Dr. Ian Gilham was Chief Executive Officer of Axis-Shield plc, the in-vitro diagnostics company acquired by Alere in November 2011 for £235M. Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008. Prior to its sale to Alere, Axis-Shield’s revenues rose above £100M and the company issued a maiden dividend. Before joining Axis-Shield, Dr. Gilham was VP Ph armacogenetics at GSK where he was responsible for the delivery of pharmacogentic tests, as well as novel diagnostic tests used in targeting GSK’s medicines. Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott L a boratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.

Commenting on his appointment, Dr. Ian Gilham, said: “I am delighted to join Biosurfit as Chairman of the Board. It is an incredibly exciting time for the company with new op portunities ahead and a chance to support an entrepreneurial team that have developed innovative and potentially game changing technologies into a great new product. Biosurfit has a tremendous potential in Point of Care Diagnostics with its spinit® instrument that is due to be launched in 2013. I l ook forward to working with the team to help Biosurfit in reaching its great ambitions.”

João Garcia da Fonseca, Founder and CEO of Biosurfit, commented: "We are all delighted to have Ian join the team, particularly as we are preparing to launch our spinit® instrument in the P oint of Care testing market. Ian is an experienced leader with an international track record in the research, development and commercialisation of diagnostic and pharmaceutical products. His wealth of experience and great knowledge of the IVD industry will be extremely valuable to Biosurfit.”
[ br]A bout Biosurfit
Biosurfit is a Venture Capital backed diagnostics company founded in 2006. The company invented and developed breakthrough technologies that enable fast, precise and affordable blood analysis, aiming for the key parameters that doctors really want. These proprietary technol ogi es ar e combined in the spinit® instrument, using a user-friendly reader and disposable disk cartridges for specific clinical conditions. The spinit® instrument uses only one drop of blood to deliver precise results within 10-15 minutes. Initial disposable cartridges to be launched in 2013 inc lude CRP, Blood Count and an Inflammation Panel. It is planned that future tests will include diabetes and cardiac multi-parameter panels.

For more information, please contact:
João Garcia da Fonseca, CEO of Biosurfit, tel: +351 217500228
Mary-Jane Elliott or Claire Dickinson, M:Commun icat ions, tel: +44 (0) 20 7920 2345

Fonte: Biosurfit press release of 04.03.2013

Prémio Idea Puzzle 2012
Nonius celebra acordo de princípio com o grupo Impresa
Agena Bioscience e HeartGenetics estabelecem parceria comercial
Biosurfit recebe a Marcação CE para teste da diabetes
A HeartGenetics foi seleccionada para a World Health Summit
Beta Capital desinveste na Nonius: uma história de sucesso
Magnomics vence maior concurso mundial de Saúde Animal
Nonius é líder na gestão de Internet para Hotéis na América Latina
Biosurfit em grande destaque no mercado Benelux
Crivo investe na Bullet Solutions

ver noticias em arquivo
ver noticias por participada
Biocant Ventures, Lda.
Biosurfit, S.A.

Quem somos

Politica de investimento
O seu projecto